Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New findings implicate cell size controls in a variety of diseases

26.11.2003


Basic research into a tumor suppressor gene that controls cell size has uncovered a link between three different genetic diseases and points to a possible treatment for all of them.



The tie that binds these three seemingly disparate medical conditions is a biochemical chain of events that govern cell size. At the end of this chain, a known drug may work to replace missing or broken parts of the biochemical chain.

"We were doing basic cell biology, investigating how cell growth is coordinated with the cell’s energy level," said Kun-Liang Guan, research professor at the University of Michigan Life Sciences Institute. "We found this story that connects all these things together in a logical manner."


Guan, who is also a professor of biological chemistry and a MacArthur Foundation fellow, and postdoctoral fellow Ken Inoki have been investigating the general question of how cell growth is regulated because it can be a factor in cancerous cell growth.

In a study published in the Nov. 26 edition of Cell, the researchers describe how a cell growth regulator gene called TSC2 responds to different levels of available energy, such as the sugar glucose. As expected, they found that TSC2 activity is stepped up in response to energy starvation, which means the cell’s growth rate is being slowed to accommodate the less favorable growing conditions.

TSC1 and TSC2 take their name from a kind of tumor. Tuberous sclerosis is a genetic disease in which benign tumors may grow in the brain and nervous system throughout a person’s life. Its severity can range from learning disabilities and epilepsy to severe mental retardation and uncontrollable seizures. There is no cure for tuberous sclerosis, but symptoms may be treated with medications to control seizures and behavior problems.

The genes TSC1 and TSC2 make two proteins that bind together to form a complex which helps control a cell’s growth and its final size. A defect in either gene can lead to tuberous sclerosis.

In watching how the cell responded to energy shortages, the Guan lab identified a molecule called AMPK that makes TSC2 work harder in starvation conditions.

Though it wasn’t known previously that AMPK was performing this function, the molecule had earlier been implicated in Wolf-Parkinson-White Syndrome, a genetic disease marked by problems in the electrical circuitry of the heart muscle and cardiac hypertrophy, an abnormally enlarged heart.

Upstream in the biochemical reaction from AMPK is another molecule known as LKB1, which was identified by other researchers. Defects in LKB1 are associated with Peutz-Jagers Syndrome, in which benign polyps proliferate in the intestines and stomach, and dark pigmentation appears around the mouth, eyes and nostrils of children under 5.

Guan earlier established that the TSC complex’s job is to limit the activity of a molecule called mTOR, which is a key player in cell growth, protein-making and viability. Now, it’s clear that these other molecules act upstream of mTOR, and that a defect in each of them means a different disease.

Taken together, the chain of events is now known to work like this:
More LKB1 means more AMPK. That means more TSC2, and that, in turn, means less mTOR, which has the result of limiting cell growth. Knock out any of those elements upstream from mTOR, and you have the opposite effect---more cell growth.

This is where Guan scoots forward in his chair excitedly. He recently learned that researchers at the Cincinnati Children’s Hospital are experimenting with the drug Rapamycin to regulate mTOR activity. He has to wonder: what if Rapamycin, which has FDA approval for use as an anti-rejection drug in organ transplants, could also be used to treat these genetic syndromes?

That is, if somebody has a genetic disorder because their AMPK or LKB is missing or malformed, could the role of regulating mTOR be replaced by the drug?

That’s the next question Guan and his team will turn to, working with their Life Sciences Institute colleagues. Guan wants to collaborate with LSI geneticist David Ginsburg on developing mice that mimic the genetic disorders so that further study can be done on the biochemical chain of events. And Guan wants to connect with LSI cell biologist Daniel Klionsky to look for parallels between this mammalian version of TOR (mTOR), and a molecule Klionsky studies in yeast called just TOR which performs similar functions.

"It will be great to have Dan as my neighbor," said Guan, whose office is just steps away from Klionsky’s on the sixth floor of the new LSI. "This is the sort of thing this institute is all about."


The paper is "TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival," Ken Inoki, Tianqing Zhu and Kun-Liang Guan, Cell, Vol. 115, Nov. 26, 2003.

Karl Leif Bates | EurekAlert!
Further information:
http://www.lsi.umich.edu
http://www.lifesciences.umich.edu/institute/labs/guan/
http://www.umich.edu/news

More articles from Health and Medicine:

nachricht Illinois team develops first of a kind in-vitro 3D neural tissue model
11.12.2019 | University of Illinois College of Engineering

nachricht Safer viruses for vaccine research and diagnosis
11.12.2019 | University of Queensland

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

Im Focus: Electronic map reveals 'rules of the road' in superconductor

Band structure map exposes iron selenide's enigmatic electronic signature

Using a clever technique that causes unruly crystals of iron selenide to snap into alignment, Rice University physicists have drawn a detailed map that reveals...

Im Focus: Developing a digital twin

University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making

In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Self-driving microrobots

11.12.2019 | Materials Sciences

Innovation boost for “learning factory”: European research project “SemI40” generates path-breaking findings

11.12.2019 | Information Technology

Molecular milk mayonnaise: How mouthfeel and microscopic properties are related in mayonnaise

11.12.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>